Athersys, Inc. (NASDAQ:ATHX) Receives Average Rating of “Buy” from Analysts

Shares of Athersys, Inc. (NASDAQ:ATHX) have received an average rating of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $9.00.

Several brokerages recently commented on ATHX. Bank of America began coverage on shares of Athersys in a research note on Thursday, June 25th. They set a “buy” rating and a $5.00 price objective for the company. BidaskClub cut shares of Athersys from a “buy” rating to a “hold” rating in a research note on Thursday, June 25th. Dawson James reaffirmed a “buy” rating and set a $12.00 price objective on shares of Athersys in a research note on Wednesday, May 6th. Smith Barney Citigroup assumed coverage on shares of Athersys in a research note on Thursday, April 23rd. They issued an “outperform” rating and a $14.00 price target for the company. Finally, ValuEngine raised shares of Athersys from a “hold” rating to a “buy” rating in a research note on Monday, June 1st.

In other Athersys news, COO William Lehmann, Jr. sold 20,000 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $2.86, for a total transaction of $57,200.00. Following the transaction, the chief operating officer now directly owns 410,720 shares of the company’s stock, valued at approximately $1,174,659.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Laura K. Campbell sold 137,894 shares of the business’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $3.81, for a total transaction of $525,376.14. Following the transaction, the insider now directly owns 561,005 shares in the company, valued at $2,137,429.05. The disclosure for this sale can be found here. Corporate insiders own 12.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in shares of Athersys in the 4th quarter worth about $28,000. Emerald Investment Partners LLC purchased a new stake in Athersys in the first quarter valued at approximately $37,000. Jane Street Group LLC purchased a new stake in Athersys in the fourth quarter valued at approximately $49,000. Advisor Group Inc. boosted its position in Athersys by 179.9% in the fourth quarter. Advisor Group Inc. now owns 41,982 shares of the biopharmaceutical company’s stock valued at $52,000 after buying an additional 26,982 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in Athersys by 181.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 47,484 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 30,638 shares during the period. 17.29% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ATHX traded up $0.01 during trading hours on Thursday, hitting $2.75. The company’s stock had a trading volume of 89,324 shares, compared to its average volume of 6,270,316. The company has a market cap of $540.32 million, a price-to-earnings ratio of -9.10 and a beta of -1.66. The business has a 50 day simple moving average of $2.86 and a two-hundred day simple moving average of $1.97. Athersys has a 52-week low of $1.13 and a 52-week high of $4.38.

Athersys (NASDAQ:ATHX) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). As a group, sell-side analysts anticipate that Athersys will post -0.32 EPS for the current year.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Read More: How a Back-End Load Mutual Fund Works

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.